- We will send in 10–14 business days.
/images/books/12960074/9783030097820.jpg)
- Author: Oliver Gassmann
- Publisher: Springer
- ISBN-10: 303009782X
- ISBN-13: 9783030097820
- Format: 15.6 x 23.4 x 1.1 cm, minkšti viršeliai
- Language: English
- SAVE -10% with code: EXTRA
Reviews
Description
Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. Our findings are illustrated by cases from Europe, the US, and Asia.
EXTRA 10 % discount with code: EXTRA
The promotion ends in 23d.00:04:40
The discount code is valid when purchasing from 10 €. Discounts do not stack.
- Author: Oliver Gassmann
- Publisher: Springer
- ISBN-10: 303009782X
- ISBN-13: 9783030097820
- Format: 15.6 x 23.4 x 1.1 cm, minkšti viršeliai
- Language: English English
Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. Our findings are illustrated by cases from Europe, the US, and Asia.
Reviews